Table 11:

Event Rates, Treatment Effects, and Severity: Hemorrhagic Stroke

Baseline Risk of Hemorrhagic Stroke
HAS-BLED Score	Annual Probability of Event	Standard Error	Source
0	0.000	0.0007a	Friberg et al, 201250
1	0.011	0.0007	Friberg et al, 201250
2	0.021	0.0008	Friberg et al, 201250
3	0.031	0.0011	Friberg et al, 201250
4	0.047	0.0023	Friberg et al, 201250
5	0.070	0.0077	Friberg et al, 201250
6	0.145	0.0408	Friberg et al, 201250
7	0.228	0.2576	Friberg et al, 201250
Treatment Effects
Intervention:Comparator	Odds Ratio	Standard Error	Source
Warfarin:aspirin	1.98	0.1289	Aguilar et al, 200753
LAAC device:warfarin	0.21	0.5659	PREVAIL, Holmes et al, 201420; PROTECT AF, Reddy et al, 201440
Apixaban:warfarin	0.51	0.1950	ARISTOTLE, Granger et al, 201116
Dabigatran 110 mg:warfarin	0.31	0.3066	RE-LY, Connolly et al, 200915
Dabigatran 150 mg:warfarin	0.26	0.3254	RE-LY, Connolly et al, 200915
Rivaroxaban:warfarin	0.58	0.2340	ROCKET AF, Patel et al, 201117
Severity of Hemorrhagic Stroke
Event and Severity	Proportion	Standard Error	Source
Proportion of hemorrhagic strokes that are:
Fatal	0.429	0.0857	Goeree et al, 200554
Major	0.119	0.0238	Goeree et al, 200554
Moderate	0.429	0.0857	Goeree et al, 200554
Minor	0.023	0.0048	Goeree et al, 200554

Abbreviations: HAS-BLED, Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratios (INRs), Elderly, Drugs or alcohol; LAAC device, left atrial appendage closure device with delivery system.

^aStandard error assumed to be the same as for a HAS-BLED score of 1.